Phase III Clinical Study of JTE-052 Ointment - Randomized Controlled and Long-Term Extension Study of JTE-052 Ointment in Japanese Pediatric Patients with Atopic Dermatitis -
Phase of Trial: Phase III
Latest Information Update: 25 Apr 2019
Price : $35 *
At a glance
- Drugs Delgocitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Sponsors Japan Tobacco
- 25 Apr 2019 According to a Torii Pharmaceutical Media Release, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. will aim to submit a marketing application for delgocitinib ointment in Japan, based on the results of this and other clinical studies.
- 25 Apr 2019 According to a Torii Pharmaceutical Media Release, Primary endpoint of Efficacy the percentage change of the mEASI score from baseline, has met superiority to the vehicle. The favorable tolerability profile on safety was obtained within the treatment period.
- 24 Aug 2018 New trial record